{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:06:18Z","timestamp":1791396378315,"version":"4.3.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11154-024-09926-5","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T20:33:01Z","timestamp":1733689981000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["No longer to be ignored: Hypophosphatemia following intravenous iron administration"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9503-0946","authenticated-orcid":false,"given":"Matthijs","family":"Strubbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-6677","authenticated-orcid":false,"given":"Karel","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Peene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6909-7539","authenticated-orcid":false,"given":"Bert","family":"Eeckhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-784X","authenticated-orcid":false,"given":"Bart","family":"Van der Schueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-4757","authenticated-orcid":false,"given":"Brigitte","family":"Decallonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-669X","authenticated-orcid":false,"given":"Roman","family":"Vangoitsenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-0104","authenticated-orcid":false,"given":"Dirk","family":"Vanderschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-2860","authenticated-orcid":false,"given":"Leen","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"154","key":"9926_CR1","first-page":"116202","volume":"2022","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone. 2021;2022(154):116202.","journal-title":"Bone"},{"issue":"19","key":"9926_CR2","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832\u201343.","journal-title":"N Engl J Med"},{"issue":"10270","key":"9926_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","volume":"397","author":"SR Pasricha","year":"2021","unstructured":"Pasricha SR, Tye-Din J, Muckenthaler MU, et al. Iron deficiency. Lancet. 2021;397(10270):233\u201348.","journal-title":"Lancet"},{"key":"9926_CR4","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/DDDT.S55499","volume":"8","author":"J Toblli","year":"2014","unstructured":"Toblli J, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"9926_CR5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","volume":"45","author":"NA Kennedy","year":"2023","unstructured":"Kennedy NA, Achebe MM, Biggar P, et al. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm. 2023;45(3):604\u201312.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"9926_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","volume":"90","author":"T Avni","year":"2015","unstructured":"Avni T, Bieber A, Grossman A, et al. The Safety of Intravenous Iron Preparations. Mayo Clin Proc. 2015;90(1):12\u201323.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"9926_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2020.1709437","volume":"13","author":"RF Pollock","year":"2020","unstructured":"Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187\u201395.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"9926_CR8","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26015","volume":"96","author":"M Wolf","year":"2021","unstructured":"Wolf M, Auerbach M, Kalra PA, et al. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA\/NEPHRO trials. Am J Hematol. 2021;96(1):E11\u20135.","journal-title":"Am J Hematol"},{"issue":"25","key":"9926_CR9","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"key":"9926_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2018.04.013","volume":"52","author":"GJL Cunha","year":"2018","unstructured":"Cunha GJL, Rocha BML, Menezes FL. Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions. Eur J Intern Med. 2018;52:1\u20137.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"9926_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"JJV McMurray","year":"2012","unstructured":"McMurray JJV, Parfrey PS, Adamson JW, et al. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279\u2013335.","journal-title":"Kidney Int Suppl."},{"issue":"6","key":"9926_CR12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","volume":"79","author":"JW Bazeley","year":"2022","unstructured":"Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis. 2022;79(6):868\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"9926_CR13","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","volume":"38","author":"JA Glaspy","year":"2021","unstructured":"Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021;38(7):3531\u201349.","journal-title":"Adv Ther"},{"issue":"4","key":"9926_CR14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","volume":"107","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Zoller H, Wolf M. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. J Clin Endocrinol Metab. 2022;107(4):1009\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9926_CR15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.4558","volume":"37","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, et al. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. J Bone Miner Res. 2022;37(6):1188\u201399.","journal-title":"J Bone Miner Res"},{"key":"9926_CR16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","volume":"16","author":"JA Glaspy","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: A systematic literature review. Ther Clin Risk Manag. 2020;16:245\u201359.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"9926_CR17","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256\u201373.","journal-title":"Br J Clin Pharmacol"},{"key":"9926_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91\u2013104.","journal-title":"Annu Rev Med"},{"issue":"1","key":"9926_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","volume":"16","author":"D Edmonston","year":"2020","unstructured":"Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16(1):7\u201319.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"9926_CR20","first-page":"437","volume":"47","author":"C Cipriani","year":"2022","unstructured":"Cipriani C, Minisola S, Colangelo L, et al. FGF23 functions and disease. Minerva Endocrinol. 2022;47(4):437\u201348.","journal-title":"Minerva Endocrinol"},{"issue":"7","key":"9926_CR21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2010.543","volume":"79","author":"AS Dusso","year":"2011","unstructured":"Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: A downward spiral in kidney disease. Kidney Int. 2011;79(7):715\u201329.","journal-title":"Kidney Int"},{"issue":"3\u20135","key":"9926_CR22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","volume":"103","author":"TK Barthel","year":"2007","unstructured":"Barthel TK, Mathern DR, Whitfield GK, et al. 1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007;103(3\u20135):381\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"9926_CR23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"key":"9926_CR24","doi-asserted-by":"publisher","unstructured":"Richter B, Faul C. FGF23 actions on target tissues-with and without Klotho. Front Endocrinol (Lausanne). 2018;9. https:\/\/doi.org\/10.3389\/fendo.2018.00189","DOI":"10.3389\/fendo.2018.00189"},{"issue":"17","key":"9926_CR25","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/ijms20174195","volume":"20","author":"B Czaya","year":"2019","unstructured":"Czaya B, Faul C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. Int J Mol Sci. 2019;20(17):4195.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9926_CR26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135\u201346.","journal-title":"Kidney Int"},{"issue":"8","key":"9926_CR27","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793\u2013803.","journal-title":"J Bone Miner Res"},{"key":"9926_CR28","doi-asserted-by":"publisher","unstructured":"Wolf M, Chertow GM, Macdougall IC et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI insight. 2018;3(23). https:\/\/doi.org\/10.1172\/jci.insight.124486","DOI":"10.1172\/jci.insight.124486"},{"issue":"7","key":"9926_CR29","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab. 2009;94(7):2332\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9926_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01643-5","volume":"18","author":"IE Emrich","year":"2020","unstructured":"Emrich IE, Lizzi F, Siegel JD, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose - The randomized controlled HOMe aFers study. BMC Med. 2020;18(1):1\u201310.","journal-title":"BMC Med"},{"issue":"5","key":"9926_CR31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA - J Am Med Assoc. 2020;323(5):432\u201343.","journal-title":"JAMA - J Am Med Assoc"},{"issue":"5","key":"9926_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ygh2.415","volume":"2","author":"KC Fragkos","year":"2020","unstructured":"Fragkos KC, Sehgal V, Rogers J, et al. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose\u2014Real world experience from a tertiary centre in the UK. GastroHep. 2020;2(5):205\u201314.","journal-title":"GastroHep"},{"issue":"7","key":"9926_CR33","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2007020143","volume":"18","author":"SM Brunelli","year":"2007","unstructured":"Brunelli SM, Goldfarb S. Hypophosphatemia. J Am Soc Nephrol. 2007;18(7):1999\u20132003.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"9926_CR34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ. Approach to the Hypophosphatemic Patient. J Clin Endocrinol Metab. 2012;97(3):696\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9926_CR35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644\u201353.","journal-title":"Gut"},{"issue":"4","key":"9926_CR36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833\u201342.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"9926_CR37","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","volume":"49","author":"LT Goodnough","year":"2009","unstructured":"Goodnough LT, Van Wyck DB, Mangione A, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009;49(12):2719\u201328.","journal-title":"Transfusion"},{"issue":"9","key":"9926_CR38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","volume":"94","author":"M Auerbach","year":"2019","unstructured":"Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007\u201314.","journal-title":"Am J Hematol"},{"issue":"3","key":"9926_CR39","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","volume":"141","author":"R Evstatiev","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-853.e2.","journal-title":"Gastroenterology"},{"issue":"1","key":"9926_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijgo.2015.09.007","volume":"133","author":"R Mahey","year":"2016","unstructured":"Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynecol Obstet. 2016;133(1):43\u20138.","journal-title":"Int J Gynecol Obstet"},{"key":"9926_CR41","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. National Cancer Institute; 2010."},{"key":"9926_CR42","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. National Cancer Institute; 2017."},{"issue":"6","key":"9926_CR43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/apt.14231","volume":"46","author":"B Schaefer","year":"2017","unstructured":"Schaefer B, Glodny B, Wolf M, et al. Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. Aliment Pharmacol Ther. 2017;46(6):641\u20133.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9926_CR44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","volume":"93","author":"NF Adkinson","year":"2018","unstructured":"Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol. 2018;93(5):683\u201390.","journal-title":"Am J Hematol"},{"issue":"1","key":"9926_CR45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","volume":"36","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111\u201320.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"9926_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","volume":"92","author":"R Derman","year":"2017","unstructured":"Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92(3):286\u201391.","journal-title":"Am J Hematol"},{"key":"9926_CR47","unstructured":"Report on Monover 100 mg\/ml, solution injectable\/pour perfusion. Haute Autorit\u00e9 de Sant\u00e9; Commission de la Transparence; 2016. p. 20\u20132."},{"issue":"1","key":"9926_CR48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-018-2501-8","volume":"109","author":"K Ikuta","year":"2019","unstructured":"Ikuta K, Hanashi H, Hirai K, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019;109(1):41\u20139.","journal-title":"Int J Hematol"},{"issue":"5","key":"9926_CR49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12185-022-03401-0","volume":"116","author":"H Kawabata","year":"2022","unstructured":"Kawabata H, Tamura T, Tamai S, et al. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. Int J Hematol. 2022;116(5):647\u201358.","journal-title":"Int J Hematol"},{"issue":"11","key":"9926_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9113587","volume":"9","author":"G Rosano","year":"2020","unstructured":"Rosano G, Schiefke I, G\u00f6hring UM, et al. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med. 2020;9(11):1\u201314.","journal-title":"J Clin Med"},{"key":"9926_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/468675","volume":"2015","author":"S Hardy","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:1\u20136.","journal-title":"Int J Rheumatol."},{"issue":"12","key":"9926_CR52","doi-asserted-by":"crossref","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","volume":"11","author":"B Schaefer","year":"2016","unstructured":"Schaefer B, W\u00fcrtinger P, Finkenstedt A, et al. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE. 2016;11(12):e0167146.","journal-title":"PLoS ONE"},{"issue":"2","key":"9926_CR53","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ehf2.14286","volume":"10","author":"GMC Rosano","year":"2023","unstructured":"Rosano GMC, Kalantar-Zadeh K, Jankowska EA. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials. ESC Hear Fail. 2023;10(2):1294\u2013304.","journal-title":"ESC Hear Fail"},{"issue":"4","key":"9926_CR54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/17843286.2022.2153465","volume":"78","author":"A Decruyenaere","year":"2023","unstructured":"Decruyenaere A, Kortbeek K, Delanghe S, et al. Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: a retrospective cohort study. Acta Clin Belgica Int J Clin Lab Med. 2023;78(4):298\u2013307.","journal-title":"Acta Clin Belgica Int J Clin Lab Med"},{"issue":"5","key":"9926_CR55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jgh3.12150","volume":"3","author":"W Fang","year":"2019","unstructured":"Fang W, McMahon LP, Bloom S, et al. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3(5):438\u201340.","journal-title":"JGH Open"},{"issue":"5","key":"9926_CR56","first-page":"340","volume":"66","author":"S G\u00f3mez Rodr\u00edguez","year":"2019","unstructured":"G\u00f3mez Rodr\u00edguez S, Castro Ramos JC, Abreu Pad\u00edn C, et al. Intravenous iron induced severe hypophosphatemia in a gastric bypass patient. Endocrinol Diabetes y Nutr (English ed). 2019;66(5):340\u20132.","journal-title":"Endocrinol Diabetes y Nutr (English ed)"},{"issue":"9","key":"9926_CR57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11695-013-0939-6","volume":"23","author":"M Malone","year":"2013","unstructured":"Malone M, Barish C, He A, et al. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg. 2013;23(9):1413\u201320.","journal-title":"Obes Surg"},{"issue":"7","key":"9926_CR58","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s11695-020-04544-x","volume":"30","author":"M Schoeb","year":"2020","unstructured":"Schoeb M, R\u00e4ss A, Frei N, et al. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study. Obes Surg. 2020;30(7):2659\u201366.","journal-title":"Obes Surg"},{"key":"9926_CR59","unstructured":"Injectafer [US package insert]. Shirley, NY: American Regent, Inc.; 2021."},{"key":"9926_CR60","unstructured":"Injectafer 50 mg\/ml dispersion for injection\/infusion [SmPC]. Paris: Vifor France; 2023."},{"issue":"1","key":"9926_CR61","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/13696998.2024.2313932","volume":"27","author":"TH Iqbal","year":"2024","unstructured":"Iqbal TH, Kennedy N, Dhar A, et al. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. J Med Econ. 2024;27(1):392\u2013403.","journal-title":"J Med Econ"},{"issue":"6","key":"9926_CR62","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2023-330061","volume":"73","author":"A Chauhan","year":"2024","unstructured":"Chauhan A, Lucas S, Garg M. Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain. Gut. 2024;73(6):1039\u20131039.","journal-title":"Gut"},{"issue":"4","key":"9926_CR63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the Treatment of Tumor-Induced Osteomalacia. J Bone Miner Res. 2021;36(4):627\u201335.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"9926_CR64","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","volume":"59","author":"R Amarnani","year":"2020","unstructured":"Amarnani R, Travis S, Javaid MK. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology (Oxford). 2020;59(8):2166\u20138.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09926-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-024-09926-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09926-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:38:33Z","timestamp":1738539513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-024-09926-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9926"],"URL":"https:\/\/doi.org\/10.1007\/s11154-024-09926-5","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"1 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of individual case reports as clinical vignettes was approved by the Research Ethics Committee UZ\/KU Leuven (MP029667). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki. Written informed consent was obtained from the individual subjects for whom identifying information is included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}